Tilray, Inc.

Tilray, Inc. (NASDAQ: TLRY) is engaged in researching, cultivating, and distributing medical cannabis. It is also a global distributer of cannabis lifestyle and consumer packaged goods. 

Key Highlights

• The company reported a YoY growth of 25.27% in revenue to USD 142.24 million in Q4FY21 (ended May 31, 2021) compared to USD 113.54 million in Q4FY20.
• TLRY reported a net income of USD 33.61 million in Q4FY21 in contrast to a net loss of USD 84.31 million in Q4FY20.
• At a special meeting on Sep 10, 2021, TLRY’s shareholders approved, increase in number of authorized shares. These additional shares will enable TLRY to carry out its strategic plan and accelerate growth and value creation.
• Its Debt/Equity ratio as of Q2FY21 was 0.21x.
• Its Q4FY21 ROE is -14.7%, whereas Peer’s Median stood at 2.6%.
• Stock is currently trading below both its 50-DMA and 200-DMA- a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 4.41 to USD 67.0.
• TLRY's share price fell 8.31% in the past month.

Technical Price Chart (as of September 15, 2021). Analysis by Kalkine

Conclusion: Considering the significant topline growth, the surge in profitability, and associated risks, we recommend a "Watch" rating on the stock at the closing price of USD 12.03, up 2.47% as of September 15, 2021.

*The reference data in this report has been partly sourced from REFINITIV.